Existing research indicates that AKT inhibition reduces PD-L1 expression in tumor cells, enhances activation and tumor infiltration of CD8+ T cells, and reduces tumor growth, accompanied by prolonged mouse survival 39. The gene discussed is CD8A; the disease is neoplasm.